Citation： 中華醫學會結核分會西南地區肺結核診療專家共識編寫組. 中國西南地區成人活動性肺結核診療專家共識. Chinese Journal of Respiratory and Critical Care Medicine, 2022, 21(9): 609-621. doi: 10.7507/1671-6205.202209068 Copy
Copyright ? the editorial department of Chinese Journal of Respiratory and Critical Care Medicine of West China Medical Publisher. All rights reserved
| 1. | Global tuberculosis report 2020. Geneva: World Health Organization; 2020. |
| 2. | National center for tuberculosis control and prevention. National TB surveillance information in 2018. Beijing. |
| 3. | 全國第五次結核病流行病學抽樣調查技術指導組, 全國第五次結核病流行病學抽樣調查辦公室. 2010年全國第五次結核病流行病學抽樣調查報告. |
| 4. | 中華人民共和國國家衛生和計劃生育委員會. WS 288-2017 肺結核診斷[M]. 2017-11-09. |
| 5. | 中華人民共和國國家衛生和計劃生育委員會. WS 196-2017 肺結核分類[M]. 2017-11-09. |
| 6. | 曹彬, 陳虹. 肺結核基層診療指南(2018年). 中華全科醫師雜志, 2019, 18(8): 709-717. |
| 7. | 汪清雅, 龐艷, 李建瓊, 等. 2014-2018年重慶市肺結核合并糖尿病病例特征分析. 預防醫學, 2021, 33(5): 476-478, 483. |
| 8. | 江麗娜, 李曉蓉, 龐學文. 肺結核潛伏性感染的診斷和預防性治療的探討. 職業與健康, 2016, 32(15): 2153-2157. |
| 9. | 楊麗佳. 結核病空間分布特征及其影響因素的研究[D]. 中國疾病預防控制中心, 2020. |
| 10. | 吳兵, 袁林, 潘映春, 等. 2009-2013年涼山州肺結核病防治狀況分析. 現代預防醫學, 2017, 44(5): 769-771, 777. |
| 11. | 楊麗佳, 李濤, 陳偉. 2011-2018年中國西部四省少數民族健康扶貧重點地區結核病疫情特征分析. 疾病監測, 2020, 35(1): 60-64. |
| 12. | 中華醫學會結核病學分會臨床檢驗專業委員會. 結核病病原學分子診斷專家共識. 中華結核和呼吸雜志, 2018, 41(9): 688-695. |
| 13. | Yasmin M, Refregier G, Siddiqui RT, et al. Reverse line probe assay for cheap detection of single nucleotide polymorphisms in Mycobacterium tuberculosis. Tuberculosis (Edinb), 2018, 110: 52-55. |
| 14. | Harries AD, Kumar AMV. Challenges and progress with diagnosing pulmonary tuberculosis in low- and middle-income countries. Diagnostics (Basel), 2018, 8(4): 78. |
| 15. | Xu KJ, Wang ST, Wu J, et al. Performance of Biochip system in detecting drug resistant and multidrug-resistant tuberculosis using sputum collected from multiple clinical settings in Zhejiang, China. Sci Rep, 2018, 8: 10587. |
| 16. | Chen XR, Hu TY. Strategies for advanced personalized tuberculosis diagnosis: current technologies and clinical approaches. Precis Clin Med, 2021, 4(1): 35-44. |
| 17. | Babafemi EO, Cherian BP, Banting L, et al. Effectiveness of real-time polymerase chain reaction assay for the detection of Mycobacterium tuberculosis in pathological samples: a systematic review and meta-analysis. Syst Rev, 2017, 6: 215. |
| 18. | Walzl G, McNerney R, du Plessis N, et al. Tuberculosis: advances and challenges in development of new diagnostics and biomarkers. Lancet Infect Dis, 2018, 18(7): e199-e210. |
| 19. | Tan YJ, Tan YH, Li JL, et al. Combined IFN-γ and IL-2 release assay for detect active pulmonary tuberculosis: a prospective multicentre diagnostic study in China. J Transl Med, 2021, 19: 289. |
| 20. | Sun Q, Wei W, Sha W. Potential role for Mycobacterium tuberculosis specific IL-2 and IFN-γ responses in discriminating between latent infection and active disease after long-term stimulation. PLoS ONE, 2016, 11(12): e0166501. |
| 21. | Chesov D, Lange C, Daduna F, et al. Combined antigen-specific interferon-γ and interleukin-2 release assay (FluoroSpot) for the diagnosis of Mycobacterium tuberculosis infection. PLoS ONE, 2015, 10(3): e0120006. |
| 22. | Li F, Xu M, Qin C, et al. Recombinant fusion ESAT6-CFP10 immunogen as a skin test reagent for tuberculosis diagnosis: an open-label, randomized, two-centre phase 2a clinical trial. Clin Microbiol Infect, 2016, 22(10): 889. e9-889. e16. |
| 23. | WHO. WHO Treatment Guidelines for Multidrug- and Rifampicin-Resistant Tuberculosis. Geneva: World Health Organization, 2018. |
| 24. | WHO. WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment. Geneva: World Health Organization, 2019. |
| 25. | 中華醫學會結核病學分會. 中國耐多藥和利福平耐藥結核病治療專家共識(2019 年版). 中華結核和呼吸雜志, 2019, 42(10): 733-749. |
| 26. | The Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, 2018, 392(10150): 821-834. |
| 27. | 中華醫學會結核病學分會重癥專業委員會. 結核病營養治療專家共識. 中華結核和呼吸雜志, 2020, 43(1): 17-26. |
| 28. | 中華醫學會結核病學分會. 結核病免疫治療專家共識(2022年版). 中華結核和呼吸雜志, 2022, 45(7): 651-666. |
| 29. | 國家衛生健康委員會辦公廳. 中國結核病預防控制工作技術規范(2020年版). 國衛辦疾控函[2020]279號. |
| 30. | Starke JR. Tuberculosis. An old disease but a new threat to the mother, fetus, and neonate. Clin Perinatol, 1997, 24(1): 107-127. |
| 31. | While A, Rees KL. Health visitors' knowledge of products to be included in the nurses' formulary. Health Visit, 1994, 67(2): 57-58. |
| 32. | Peng WS, Yang J, Liu EM. Analysis of 170 cases of congenital TB reported in the literature between 1946 and 2009. Pediatr Pulmonol, 2011, 46(12): 1215-1224. |
| 33. | àlvarez-León E, Espinosa-Vega E, Santana-Rodríguez é, et al. Screening for tuberculosis infection in spanish healthcare workers: comparison of the QuantiFERON-TB gold in-tube test with the tuberculin skin test. Infect Control Hosp Epidemiol, 2009, 30(9): 876-883. |
| 34. | Janssens JP. Clinical utility of the interferon-γ release assay for elderly patients with active tuberculosis: a word of caution. Chest, 2008, 134(2): 471-472. |
| 35. | Gupta A, Montepiedra G, Theron G. HIV, pregnancy, and isoniazid preventive therapy. N Engl J Med, 2020, 382: 1184-1185. |
| 36. | Nhan-Chang CL, Jones TB. Tuberculosis in pregnancy. Clin Obstet Gynecol, 2010, 53(2): 311-321. |
| 37. | Llewelyn M, Cropley I, Wilkinson RJ, et al. Tuberculosis diagnosed during pregnancy: a prospective study from London. Thorax, 2000, 55: 129-132. |
| 38. | Sobhy S, Babiker Z, Zamora J, et al. Maternal and perinatal mortality and morbidity associated with tuberculosis during pregnancy and the postpartum period: a systematic review and meta-analysis. BJOG, 2017, 124(5): 727-733. |
| 39. | Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis, 2016, 63(7): e147-e195. |
| 40. | Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev, 2010, 2010(1): CD000171. |
| 41. | Brassard P, Hottes TS, Lalonde RG, et al. Tuberculosis screening and active tuberculosis among HIV-infected persons in a Canadian tertiary care centre. Can J Infect Dis Med Microbiol, 2009, 20(2): 51-57. |
| 42. | Boyd AE, Bothamley GH. The diagnosis of latent tuberculosis in HIV-infected persons. Clin Infect Dis, 2006, 42(10): 1498-1500. |
| 43. | Noubiap JJ, Nansseu J R, Nyaga UF, et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2.3 million patients with tuberculosis. Lancet Glob Health, 2019, 7(4): e448-e460. |
| 44. | Wang JY, Lee MC, Shu CC, et al. Optimal duration of anti-TB treatment in patients with diabetes: nine or six months?. Chest, 2015, 147(2): 520-528. |
| 45. | 馬秀玲. 肺結核強化治療對乙肝病毒攜帶者肝功能的影響. 中國基層醫藥, 2004, 11(4): 448-449. |
| 46. | Chen LB, Bao DJ, Gu L, et al. Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment. BMC Infect Dis, 2018, 18: 295. |
| 47. | Naeye RL. Infants of prolonged gestation. A necropsy study. Arch Pathol, 1967, 84(1): 37-41. |
| 48. | 毛翎, 彭莉君, 王煥強. 塵肺病治療中國專家共識(2018年版). 環境與職業醫學, 2018, 35(8): 677-689. |
| 49. | Guidelines on the Management of Latent Tuberculosis Infection[M]. Geneva: World Health Organization, 2015. |
| 50. | Jolliffe DA, Stefanidis C, Wang ZC, et al. Vitamin D metabolism is dysregulated in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2020, 202(3): 371-382. |
| 51. | Christopoulos AI, Diamantopoulos AA, Dimopoulos PA, et al. Risk factors for tuberculosis in dialysis patients: a prospective multi-center clinical trial. BMC Nephrol, 2009, 10: 36. |
| 52. | 方剛, 胡春梅, 黃莉莉, 等. 尿毒癥合并肺結核患者的臨床特點及治療. 實用臨床醫藥雜志, 2018, 22(21): 143-145. |
| 53. | Lal MK, Singh S. Tuberculosis in chronic kidney disease. J Assoc Physicians India, 2020, 68(2): 16-18. |
| 54. | Venkata RKC, Kumar S, Krishna RP, et al. Tuberculosis in chronic kidney disease. Clin Nephrol, 2007, 67: 217-220. |
- 1. Global tuberculosis report 2020. Geneva: World Health Organization; 2020.
- 2. National center for tuberculosis control and prevention. National TB surveillance information in 2018. Beijing.
- 3. 全國第五次結核病流行病學抽樣調查技術指導組, 全國第五次結核病流行病學抽樣調查辦公室. 2010年全國第五次結核病流行病學抽樣調查報告.
- 4. 中華人民共和國國家衛生和計劃生育委員會. WS 288-2017 肺結核診斷[M]. 2017-11-09.
- 5. 中華人民共和國國家衛生和計劃生育委員會. WS 196-2017 肺結核分類[M]. 2017-11-09.
- 6. 曹彬, 陳虹. 肺結核基層診療指南(2018年). 中華全科醫師雜志, 2019, 18(8): 709-717.
- 7. 汪清雅, 龐艷, 李建瓊, 等. 2014-2018年重慶市肺結核合并糖尿病病例特征分析. 預防醫學, 2021, 33(5): 476-478, 483.
- 8. 江麗娜, 李曉蓉, 龐學文. 肺結核潛伏性感染的診斷和預防性治療的探討. 職業與健康, 2016, 32(15): 2153-2157.
- 9. 楊麗佳. 結核病空間分布特征及其影響因素的研究[D]. 中國疾病預防控制中心, 2020.
- 10. 吳兵, 袁林, 潘映春, 等. 2009-2013年涼山州肺結核病防治狀況分析. 現代預防醫學, 2017, 44(5): 769-771, 777.
- 11. 楊麗佳, 李濤, 陳偉. 2011-2018年中國西部四省少數民族健康扶貧重點地區結核病疫情特征分析. 疾病監測, 2020, 35(1): 60-64.
- 12. 中華醫學會結核病學分會臨床檢驗專業委員會. 結核病病原學分子診斷專家共識. 中華結核和呼吸雜志, 2018, 41(9): 688-695.
- 13. Yasmin M, Refregier G, Siddiqui RT, et al. Reverse line probe assay for cheap detection of single nucleotide polymorphisms in Mycobacterium tuberculosis. Tuberculosis (Edinb), 2018, 110: 52-55.
- 14. Harries AD, Kumar AMV. Challenges and progress with diagnosing pulmonary tuberculosis in low- and middle-income countries. Diagnostics (Basel), 2018, 8(4): 78.
- 15. Xu KJ, Wang ST, Wu J, et al. Performance of Biochip system in detecting drug resistant and multidrug-resistant tuberculosis using sputum collected from multiple clinical settings in Zhejiang, China. Sci Rep, 2018, 8: 10587.
- 16. Chen XR, Hu TY. Strategies for advanced personalized tuberculosis diagnosis: current technologies and clinical approaches. Precis Clin Med, 2021, 4(1): 35-44.
- 17. Babafemi EO, Cherian BP, Banting L, et al. Effectiveness of real-time polymerase chain reaction assay for the detection of Mycobacterium tuberculosis in pathological samples: a systematic review and meta-analysis. Syst Rev, 2017, 6: 215.
- 18. Walzl G, McNerney R, du Plessis N, et al. Tuberculosis: advances and challenges in development of new diagnostics and biomarkers. Lancet Infect Dis, 2018, 18(7): e199-e210.
- 19. Tan YJ, Tan YH, Li JL, et al. Combined IFN-γ and IL-2 release assay for detect active pulmonary tuberculosis: a prospective multicentre diagnostic study in China. J Transl Med, 2021, 19: 289.
- 20. Sun Q, Wei W, Sha W. Potential role for Mycobacterium tuberculosis specific IL-2 and IFN-γ responses in discriminating between latent infection and active disease after long-term stimulation. PLoS ONE, 2016, 11(12): e0166501.
- 21. Chesov D, Lange C, Daduna F, et al. Combined antigen-specific interferon-γ and interleukin-2 release assay (FluoroSpot) for the diagnosis of Mycobacterium tuberculosis infection. PLoS ONE, 2015, 10(3): e0120006.
- 22. Li F, Xu M, Qin C, et al. Recombinant fusion ESAT6-CFP10 immunogen as a skin test reagent for tuberculosis diagnosis: an open-label, randomized, two-centre phase 2a clinical trial. Clin Microbiol Infect, 2016, 22(10): 889. e9-889. e16.
- 23. WHO. WHO Treatment Guidelines for Multidrug- and Rifampicin-Resistant Tuberculosis. Geneva: World Health Organization, 2018.
- 24. WHO. WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment. Geneva: World Health Organization, 2019.
- 25. 中華醫學會結核病學分會. 中國耐多藥和利福平耐藥結核病治療專家共識(2019 年版). 中華結核和呼吸雜志, 2019, 42(10): 733-749.
- 26. The Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, 2018, 392(10150): 821-834.
- 27. 中華醫學會結核病學分會重癥專業委員會. 結核病營養治療專家共識. 中華結核和呼吸雜志, 2020, 43(1): 17-26.
- 28. 中華醫學會結核病學分會. 結核病免疫治療專家共識(2022年版). 中華結核和呼吸雜志, 2022, 45(7): 651-666.
- 29. 國家衛生健康委員會辦公廳. 中國結核病預防控制工作技術規范(2020年版). 國衛辦疾控函[2020]279號.
- 30. Starke JR. Tuberculosis. An old disease but a new threat to the mother, fetus, and neonate. Clin Perinatol, 1997, 24(1): 107-127.
- 31. While A, Rees KL. Health visitors' knowledge of products to be included in the nurses' formulary. Health Visit, 1994, 67(2): 57-58.
- 32. Peng WS, Yang J, Liu EM. Analysis of 170 cases of congenital TB reported in the literature between 1946 and 2009. Pediatr Pulmonol, 2011, 46(12): 1215-1224.
- 33. àlvarez-León E, Espinosa-Vega E, Santana-Rodríguez é, et al. Screening for tuberculosis infection in spanish healthcare workers: comparison of the QuantiFERON-TB gold in-tube test with the tuberculin skin test. Infect Control Hosp Epidemiol, 2009, 30(9): 876-883.
- 34. Janssens JP. Clinical utility of the interferon-γ release assay for elderly patients with active tuberculosis: a word of caution. Chest, 2008, 134(2): 471-472.
- 35. Gupta A, Montepiedra G, Theron G. HIV, pregnancy, and isoniazid preventive therapy. N Engl J Med, 2020, 382: 1184-1185.
- 36. Nhan-Chang CL, Jones TB. Tuberculosis in pregnancy. Clin Obstet Gynecol, 2010, 53(2): 311-321.
- 37. Llewelyn M, Cropley I, Wilkinson RJ, et al. Tuberculosis diagnosed during pregnancy: a prospective study from London. Thorax, 2000, 55: 129-132.
- 38. Sobhy S, Babiker Z, Zamora J, et al. Maternal and perinatal mortality and morbidity associated with tuberculosis during pregnancy and the postpartum period: a systematic review and meta-analysis. BJOG, 2017, 124(5): 727-733.
- 39. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis, 2016, 63(7): e147-e195.
- 40. Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev, 2010, 2010(1): CD000171.
- 41. Brassard P, Hottes TS, Lalonde RG, et al. Tuberculosis screening and active tuberculosis among HIV-infected persons in a Canadian tertiary care centre. Can J Infect Dis Med Microbiol, 2009, 20(2): 51-57.
- 42. Boyd AE, Bothamley GH. The diagnosis of latent tuberculosis in HIV-infected persons. Clin Infect Dis, 2006, 42(10): 1498-1500.
- 43. Noubiap JJ, Nansseu J R, Nyaga UF, et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2.3 million patients with tuberculosis. Lancet Glob Health, 2019, 7(4): e448-e460.
- 44. Wang JY, Lee MC, Shu CC, et al. Optimal duration of anti-TB treatment in patients with diabetes: nine or six months?. Chest, 2015, 147(2): 520-528.
- 45. 馬秀玲. 肺結核強化治療對乙肝病毒攜帶者肝功能的影響. 中國基層醫藥, 2004, 11(4): 448-449.
- 46. Chen LB, Bao DJ, Gu L, et al. Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment. BMC Infect Dis, 2018, 18: 295.
- 47. Naeye RL. Infants of prolonged gestation. A necropsy study. Arch Pathol, 1967, 84(1): 37-41.
- 48. 毛翎, 彭莉君, 王煥強. 塵肺病治療中國專家共識(2018年版). 環境與職業醫學, 2018, 35(8): 677-689.
- 49. Guidelines on the Management of Latent Tuberculosis Infection[M]. Geneva: World Health Organization, 2015.
- 50. Jolliffe DA, Stefanidis C, Wang ZC, et al. Vitamin D metabolism is dysregulated in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2020, 202(3): 371-382.
- 51. Christopoulos AI, Diamantopoulos AA, Dimopoulos PA, et al. Risk factors for tuberculosis in dialysis patients: a prospective multi-center clinical trial. BMC Nephrol, 2009, 10: 36.
- 52. 方剛, 胡春梅, 黃莉莉, 等. 尿毒癥合并肺結核患者的臨床特點及治療. 實用臨床醫藥雜志, 2018, 22(21): 143-145.
- 53. Lal MK, Singh S. Tuberculosis in chronic kidney disease. J Assoc Physicians India, 2020, 68(2): 16-18.
- 54. Venkata RKC, Kumar S, Krishna RP, et al. Tuberculosis in chronic kidney disease. Clin Nephrol, 2007, 67: 217-220.